Is Agilent Technologies stock a Buy, Sell or Hold?
Agilent Technologies stock has received a consensus rating of buy. The average rating score is and is based on 28 buy ratings, 5 hold ratings, and 0 sell ratings.What was the 52-week low for Agilent Technologies stock?
The low in the last 52 weeks of Agilent Technologies stock was 112.64. According to the current price, Agilent Technologies is 118.24% away from the 52-week low.What was the 52-week high for Agilent Technologies stock?
The high in the last 52 weeks of Agilent Technologies stock was 160.08. According to the current price, Agilent Technologies is 83.20% away from the 52-week high.What are analysts forecasts for Agilent Technologies stock?
The 33 analysts offering price forecasts for Agilent Technologies have a median target of 159.09, with a high estimate of 200.00 and a low estimate of 130.00. The median estimate represents a 83.71 difference from the last price of 133.18.Agilent Technologies Stock Snapshot
133.14
Bid
900.00
Bid Size
133.18
Ask
7,500.00
Ask Size
3/17/2023
Date
4:15 PM
Time
962,593.00
Volume
136.82
Prev. Close
136.89
Open
39.65 B
Market Cap
295.70 M
Number of Shares
132.75
Day Low
136.92
Day High
133.18
112.64
52 Week Low
160.08
52 Week High
133.18
0.89
Dividend
0.64
Dividend Yield
26.33
P/E Ratio
99.62
Free Float in %
5.69
EPS 2023
21.28
Book Value per Share
5.79
Cash Flow per Share
Agilent Technologies News More News
Agilent Technologies Historical Prices
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:
0%
0
Agilent Technologies Analyst Data
Total Analysts: 33
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 130.00
Median: 159.09
Highest: 200.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Agilent Technologies Analyst Opinions
- All
- Buy
- Hold
- Sell
| 03/01/23 | Baird Patrick & Co | Maintained Buy | $174 | ||
| 03/01/23 | Credit Suisse | Maintained Buy | $170 | ||
| 01/10/23 | Wells Fargo & Co | Upgraded to Buy | $170 | ||
| 01/06/23 | SVB Leerink | Maintained Buy | $170 | ||
| 12/20/22 | UBS | Maintained Buy | $170 | ||
| 11/22/22 | Citigroup Corp. | Maintained Hold | $150 | ||
| 11/22/22 | SVB Leerink | Maintained Buy | $160 | ||
| 08/25/22 | Credit Suisse | Maintained Buy | $165 | ||
| 08/17/22 | Bank of America Merrill Lynch | Maintained Buy | $155 | ||
| 08/17/22 | Citigroup Corp. | Maintained Hold | $145 | ||
| 08/17/22 | Baird Patrick & Co | Maintained Buy | $160 | ||
| 08/17/22 | Wells Fargo & Co | Maintained Hold | $135 | ||
| 07/20/22 | UBS | Maintained Buy | $139 | ||
| 07/14/22 | Goldman Sachs | Maintained Buy | $140 | ||
| 07/08/22 | Citigroup Corp. | Downgraded to Hold | $140 | ||
| 05/25/22 | Baird Patrick & Co | Maintained Buy | $161 | ||
| 04/25/22 | Wells Fargo & Co | Downgraded to Hold | $130 | ||
| 02/23/22 | Wells Fargo & Co | Maintained Buy | $160 | ||
| 02/23/22 | Stifel, Nicolaus & Co., Inc. | Maintained Buy | $145 | ||
| 02/23/22 | Citigroup Corp. | Maintained Buy | $175 | ||
| 02/23/22 | SVB Leerink | Maintained Buy | $145 | ||
| 11/23/21 | SVB Leerink | Maintained Buy | $175 | ||
| 09/17/21 | Cowen and Company, LLC | Maintained Buy | $200 | ||
| 08/18/21 | Jefferies & Company Inc. | Maintained Buy | $185 | ||
| 08/18/21 | Baird Patrick & Co | Maintained Buy | $170 | ||
| 08/18/21 | Stifel, Nicolaus & Co., Inc. | Maintained Buy | $162 | ||
| 08/18/21 | Wells Fargo & Co | Maintained Buy | $180 | ||
| 08/18/21 | SVB Leerink | Maintained Buy | $170 | ||
| 05/26/21 | Citigroup Corp. | Maintained Buy | $160 | ||
| 05/26/21 | Baird Patrick & Co | Maintained Buy | $144 | ||
| 05/26/21 | Wells Fargo & Co | Maintained Buy | $150 | ||
| 05/26/21 | SVB Leerink | Maintained Buy | $145 | ||
| 03/18/21 | Citigroup Corp. | Upgraded to Buy | $150 |
Agilent Technologies Estimates* in USD
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Revenue | 7,092 | 7,578 | 8,115 | 8,605 |
| Dividend | 0.89 | 0.96 | 0.98 | - |
| Dividend Yield (in %) | 0.64 % | 0.69 % | 0.71 % | - |
| EPS | 5.69 | 6.31 | - | 7.75 |
| P/E Ratio | 23.67 | 21.35 | 19.43 | 17.37 |
| EBIT | 1,994 | 2,185 | 2,375 | 2,553 |
| EBITDA | 2,135 | 2,342 | 2,534 | 2,721 |
| Net Profit | 1,685 | 1,843 | 2,026 | 2,133 |
| Net Profit Adjusted | 1,685 | 1,843 | 2,026 | 2,133 |
| Pre-Tax Profit | 1,954 | 2,141 | 2,353 | 2,473 |
| Net Profit (Adjusted) | 1,842 | 2,039 | 2,278 | - |
| EPS (Non-GAAP) ex. SOE | 5.69 | 6.31 | - | 7.75 |
| EPS (GAAP) | 5.12 | 5.72 | 6.58 | - |
| Gross Income | 4,023 | 4,312 | 4,660 | 5,107 |
| Cash Flow from Investing | -465 | -311 | -313 | - |
| Cash Flow from Operations | 1,662 | 2,049 | 2,217 | - |
| Cash Flow from Financing | -431 | -837 | -1,021 | - |
| Cash Flow per Share | 5.79 | 7.11 | 7.78 | - |
| Free Cash Flow | 1,166 | 1,734 | 1,893 | - |
| Free Cash Flow per Share | 4.30 | 5.90 | 6.62 | - |
| Book Value per Share | 21.28 | 23.36 | 25.87 | - |
| Net Debt | 965 | 447 | -87 | - |
| Research & Development Exp. | - | - | - | 533 |
| Capital Expenditure | 472 | 338 | 322 | - |
| Selling, General & Admin. Exp. | - | - | - | 1,854 |
| Shareholder’s Equity | 6,418 | 6,875 | 7,497 | - |
| Total Assets | 11,724 | 12,617 | 13,468 | - |
| Previous Quarter |
Current Quarter ending 01/31/23 |
Next Quarter ending 04/30/23 |
Current Year ending 10/31/23 |
Next Year ending 10/31/24 |
|
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | - | 17 | 16 | 16 | 16 |
| Average Estimate | - | 1.311 USD | 1.262 USD | 5.690 USD | 6.308 USD |
| Year Ago | - | 1.210 USD | 1.130 USD | 5.220 USD | 5.690 USD |
| Publish Date | - | 2/28/2023 | 5/23/2023 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | - | 15 | 14 | 15 | 15 |
| Average Estimate | - | 1,700 USD | 1,672 USD | 7,092 USD | 7,578 USD |
| Year Ago | - | 1,667 USD | 1,604 USD | 6,836 USD | 7,092 USD |
| Publish Date | - | 2/28/2023 | 5/23/2023 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Agilent Technologies Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| Grau Dominique | 01/22/2023 | 52,286.84 | 40,091.69 | 159.06 | Sell | No |
| Grau Dominique | 01/22/2023 | 52,286.84 | 52,286.84 | 159.06 | Buy | No |
| Ancher-Jensen Henrik | 12/13/2022 | 29,500.00 | 70,793.03 | 155.78 | Sell | No |
| MCDONNELL PADRAIG | 12/12/2022 | 672.00 | 15,529.00 | 160.00 | Sell | No |
| Grau Dominique | 12/12/2022 | 4,000.00 | 92,378.53 | 159.20 | Sell | No |
| KOH BOON HWEE | 12/05/2022 | 13,000.00 | 57,752.10 | 152.21 | Sell | No |
| Thaysen Jacob | 11/30/2022 | 3,235.00 | 84,464.34 | 155.65 | Sell | No |
| Thaysen Jacob | 11/29/2022 | 9,700.00 | 87,699.34 | 154.63 | Sell | No |
| FIELDS HEIDI | 11/22/2022 | 3,635.00 | 54,484.15 | 155.84 | Sell | No |
| Gonsalves Rodney | 11/22/2022 | 924.00 | n/a | 155.35 | Sell | No |
| Gonsalves Rodney | 11/22/2022 | 924.00 | 27,522.92 | 155.35 | Sell | No |
| Gonsalves Rodney | 11/22/2022 | 4,634.00 | 28,446.92 | 156.20 | Sell | No |
| Gonsalves Rodney | 11/22/2022 | 924.00 | 924.00 | 155.35 | Buy | No |
| McMullen Michael R. | 11/21/2022 | 128,726.00 | 260,691.10 | 155.73 | Sell | No |
| Tang Michael | 11/21/2022 | 7,545.00 | 46,499.09 | 153.90 | Sell | No |
| MCDONNELL PADRAIG | 11/21/2022 | 2,746.00 | 16,201.00 | 153.21 | Sell | No |
| McMullen Michael R. | 11/21/2022 | 128,726.00 | 389,417.10 | 40.80 | Buy | No |
| Thaysen Jacob | 11/17/2022 | 1,418.00 | 97,399.34 | 146.19 | Sell | No |
| Grau Dominique | 11/17/2022 | 1,067.00 | 96,378.53 | 146.19 | Sell | No |
| McMahon Robert W. | 11/17/2022 | 1,750.00 | 116,057.45 | 146.19 | Sell | No |
| Raha Samraat S. | 11/17/2022 | 1,120.00 | 79,096.23 | 146.19 | Sell | No |
| Gonsalves Rodney | 11/17/2022 | 367.00 | 33,080.92 | 146.19 | Sell | No |
| Ancher-Jensen Henrik | 11/17/2022 | 995.00 | 100,293.03 | 146.19 | Sell | No |
| Tang Michael | 11/17/2022 | 1,050.00 | 54,044.09 | 146.19 | Sell | No |
| McMullen Michael R. | 11/17/2022 | 7,492.00 | 260,691.10 | 146.19 | Sell | No |
Agilent Technologies Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2022 | Agilent Technologies Inc. | 0.84 | 0.61 | USD |
| 2021 | Agilent Technologies Inc. | 0.78 | 0.49 | USD |
| 2020 | Agilent Technologies Inc. | 0.72 | 0.71 | USD |
| 2019 | Agilent Technologies Inc. | 0.66 | 0.87 | USD |
| 2018 | Agilent Technologies Inc. | 0.60 | 0.92 | USD |
| 2017 | Agilent Technologies Inc. | 0.53 | 0.78 | USD |
| 2016 | Agilent Technologies Inc. | 0.46 | 1.06 | USD |
| 2015 | Agilent Technologies Inc. | 0.40 | 1.06 | USD |
| 2014 | Agilent Technologies Inc. | 0.53 | 0.96 | USD |
| 2014 | Agilent Technologies Inc. | 0.53 | 2.17 | USD |
| 2013 | Agilent Technologies Inc. | 0.46 | 0.91 | USD |
| 2012 | Agilent Technologies Inc. | 0.30 | 0.83 | USD |
| 2011 | Agilent Technologies Inc. | - | - | USD |
| 2010 | Agilent Technologies Inc. | - | - | USD |
| 2009 | Agilent Technologies Inc. | - | - | USD |
| 2008 | Agilent Technologies Inc. | - | - | USD |
| 2007 | Agilent Technologies Inc. | - | - | USD |
| 2006 | Agilent Technologies Inc. | - | - | USD |
| 2005 | Agilent Technologies Inc. | - | - | USD |
| 2004 | Agilent Technologies Inc. | - | - | USD |
| 2003 | Agilent Technologies Inc. | - | - | USD |
*Yield of the Respective Date
Agilent Technologies Inc. Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | 1.262 USD | Q2 2023 Earnings Release | 05/23/2023 |
| Earnings Report | - | Q3 2023 Earnings Release | 08/15/2023 |
| Earnings Report | - | Q4 2023 Earnings Release | 11/20/2023 |
| Earnings Report | - | Q1 2024 Earnings Release | 02/20/2024 |
Agilent Technologies Inc. Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Annual General Meeting | - | Annual General Meeting | 03/15/2023 |
| Earnings Report | 1.370 USD | Q1 2023 Earnings Release | 02/28/2023 |
| Press Conference | - | - | 02/28/2023 |
| Press Conference | - | - | 11/21/2022 |
| Press Conference | - | - | 05/24/2022 |
Agilent Technologies Profile
Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA. .
Moody’s Daily Credit Risk Score
Agilent Technologies Shareholder
| Owner | in % |
|---|---|
| Freefloat | 99.62 |
| Vanguard Group, Inc. (Subfiler) | 8.11 |
| Wellington Management Co. LLP | 4.53 |
| State Street Corp. | 4.43 |
| Pershing Square Capital Management LP | 3.95 |
| BlackRock Fund Advisors | 3.17 |
| T. Rowe Price Investment Management, Inc. | 3.14 |
| Vanguard Total Stock Market Index Fund | 3.06 |
| Massachusetts Financial Services Co. | 2.66 |
| T. Rowe Price Associates, Inc. (Investment Management) | 2.60 |
| BlackRock Institutional Trust Co. NA | 2.42 |
| Vanguard 500 Index Fund | 2.32 |
| Geode Capital Management LLC | 2.05 |
| Blackrock Group Ltd. (Subfiler) | 1.86 |
| Pictet Asset Management SA | 1.83 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
Agilent Technologies Management
| Name | Job |
|---|---|
| Rodney Gonsalves | Chief Accounting Officer, VP & Controller |
| Robert W. McMahon | Chief Financial Officer & Senior Vice President |
| Katharine Knobil | Chief Medical Officer |
| Darlene J. S. Solomon | Chief Technology Officer & Senior Vice President |
| Otis W. Brawley | Independent Director |
| Daniel K. Podolsky | Independent Director |
| Hans Edgar Bishop | Independent Director |
| Dow R. Wilson | Independent Director |
| Mala Anand | Independent Director |
| Sue H. Rataj | Independent Director |
| Heidi Kunz Fields | Independent Director |
| Mikael Dolsten | Independent Director |
| George A. Scangos | Independent Director |
| Boon Hwee Koh | Non-Executive Chairman |
| Michael R. McMullen | President, Chief Executive Officer & Director |
| Padraig Mcdonnell | SVP & President-Agilent Cross Lab Group |
| Samraat S Raha | SVP & President-Diagnostic & Genomics Group |
| Jacob Thaysen | SVP & President-Life Sciences & Applied Markets |
| Henrik Ancher-Jensen | SVP & President-Order Fulfillment & Supply Chain |
| Michael Tang | Secretary, Senior Vice President & General Counsel |
| Jenipher E. Dalton | Senior VP-Global Quality & Regulatory Affairs |
| Allison Ballmer | Senior VP-Strategy & Corporate Development |
| Dominique P. Grau | Senior Vice President-HR & Global Communications |
| Guillermo Gualino | Treasurer & Vice President |
| Stephen Bonovich | Vice President-Global Taxation |
| Parmeet Ahuja | Vice President-Investor Relations |